BR122018015003B8 - kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais - Google Patents
kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus saisInfo
- Publication number
- BR122018015003B8 BR122018015003B8 BR122018015003A BR122018015003A BR122018015003B8 BR 122018015003 B8 BR122018015003 B8 BR 122018015003B8 BR 122018015003 A BR122018015003 A BR 122018015003A BR 122018015003 A BR122018015003 A BR 122018015003A BR 122018015003 B8 BR122018015003 B8 BR 122018015003B8
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- valsartan
- pharmaceutical compositions
- salts
- nep inhibitor
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a invenção refere-se um kit compreendendo em recipientes separados em uma embalagem única composições farmacêuticas, em que a composição farmacêutica do primeiro recipiente compreende éster etílico do ácido n-(3-carbóxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-2r-metilbutanóico ou um sal farmaceuticamente aceitável dele e a composição farmacêutica do segundo recipiente compreende valsartan ou um sal farmaceuticamente aceitável dele.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34966002P | 2002-01-17 | 2002-01-17 | |
US60/349,660 | 2002-01-17 | ||
PCT/EP2003/000415 WO2003059345A1 (en) | 2002-01-17 | 2003-01-16 | Pharmaceutical compositions comprising valsartan and nep inhibitors |
BRPI0306907 | 2003-01-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR122018015003B1 BR122018015003B1 (pt) | 2018-11-21 |
BR122018015003B8 true BR122018015003B8 (pt) | 2021-07-27 |
Family
ID=23373410
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0306907A BRPI0306907B8 (pt) | 2002-01-17 | 2003-01-16 | composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais |
BR122018015003A BR122018015003B8 (pt) | 2002-01-17 | 2003-01-16 | kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0306907A BRPI0306907B8 (pt) | 2002-01-17 | 2003-01-16 | composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1467728B1 (pt) |
JP (2) | JP4820056B2 (pt) |
KR (2) | KR20100057704A (pt) |
CN (2) | CN102091330B (pt) |
AT (1) | ATE370732T1 (pt) |
AU (1) | AU2003206738C1 (pt) |
BE (1) | BE2016C025I2 (pt) |
BR (2) | BRPI0306907B8 (pt) |
CA (1) | CA2472399C (pt) |
CO (1) | CO5600999A2 (pt) |
CY (2) | CY1106959T1 (pt) |
DE (1) | DE60315795T2 (pt) |
DK (1) | DK1467728T3 (pt) |
EC (1) | ECSP045190A (pt) |
ES (1) | ES2290429T3 (pt) |
FR (1) | FR16C0019I2 (pt) |
HU (1) | HUS1600024I1 (pt) |
IL (2) | IL162661A0 (pt) |
LU (1) | LU93074I2 (pt) |
MX (1) | MXPA04006917A (pt) |
NL (1) | NL300811I2 (pt) |
NO (2) | NO333191B1 (pt) |
NZ (1) | NZ533968A (pt) |
PL (1) | PL212318B1 (pt) |
PT (1) | PT1467728E (pt) |
RU (1) | RU2334513C3 (pt) |
SI (1) | SI1467728T1 (pt) |
WO (1) | WO2003059345A1 (pt) |
ZA (1) | ZA200405117B (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005256634B2 (en) * | 2004-06-23 | 2010-12-09 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists |
ES2397552T3 (es) * | 2004-12-24 | 2013-03-07 | Krka | Composición farmacéutica sólida que comprende valsartán |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
WO2007045663A2 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
WO2007106708A2 (en) * | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
CZ300801B6 (cs) * | 2006-06-07 | 2009-08-12 | Helvetia Pharma A.S. | Kompozice s valsartanem v pevných lékových formách |
AR064842A1 (es) | 2007-01-12 | 2009-04-29 | Mazzucco Gavieiro Maria Belen | Pirrolidin-2-onas, y su uso en la preparacion de inhibidores de nep |
GB0708507D0 (en) | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
EP2217205B1 (en) | 2007-11-06 | 2015-03-04 | Novartis AG | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
CN101774941A (zh) * | 2009-01-13 | 2010-07-14 | 浙江九洲药业股份有限公司 | 2-酰基氨基-3-联苯基丙酸的制备及拆分方法 |
ES2582395T3 (es) | 2009-05-28 | 2016-09-12 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
BR112013004164A2 (pt) | 2010-08-23 | 2016-05-10 | Novartis Ag | processo para a preparação de intermediários para a produção de inibidores da nep |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
CA2882771C (en) | 2012-08-24 | 2021-02-23 | Novartis Ag | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
EP2956464B1 (en) | 2013-02-14 | 2018-03-28 | Novartis AG | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
AU2014216417B2 (en) | 2013-02-14 | 2016-05-12 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
CN104230865B (zh) * | 2013-06-13 | 2018-01-09 | 上海翰森生物医药科技有限公司 | 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途 |
PT3038654T (pt) | 2013-08-26 | 2020-02-04 | Novartis Ag | Nova utilização |
EP3038653A1 (en) | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
CN106458857A (zh) * | 2014-08-27 | 2017-02-22 | 上海翰森生物医药科技有限公司 | AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用 |
WO2016037098A1 (en) * | 2014-09-04 | 2016-03-10 | Concert Pharmaceuticals, Inc. | Deuterated sacubitril |
CN106414416B (zh) * | 2014-09-09 | 2020-03-27 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
CN105503760A (zh) * | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
PT3218351T (pt) | 2014-11-14 | 2019-09-26 | Zentiva Ks | Um método para a preparação, isolamento e purificação de formas farmaceuticamente aplicáveis de ahu-377 |
WO2016086798A1 (zh) * | 2014-12-03 | 2016-06-09 | 上海翰森生物医药科技有限公司 | Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用 |
PT3229799T (pt) * | 2014-12-08 | 2019-01-29 | Crystal Pharmatech Co Ltd | Formas cristalinas de complexo supramolecular trissódico compreendendo valsartan e ahu-377 e métodos das mesmas |
CN105693543B (zh) * | 2014-12-15 | 2018-08-10 | 四川海思科制药有限公司 | 沙库比曲类衍生物、其药物组合物、制备方法及用途 |
CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
CN106138069A (zh) * | 2015-04-21 | 2016-11-23 | 刘春丽 | 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷 |
WO2016181284A1 (en) | 2015-05-11 | 2016-11-17 | Novartis Ag | Sacubitril-valsartan dosage regimen for treating heart failure |
US20180140579A1 (en) | 2015-05-29 | 2018-05-24 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
CN106389374A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种含有lcz696的药物组合物及其制备方法 |
US10596151B2 (en) | 2015-08-28 | 2020-03-24 | Novartis Ag | Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme |
WO2017036420A1 (zh) * | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
CN105348209B (zh) * | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
BR112018011788A2 (pt) | 2015-12-11 | 2018-12-04 | Zentiva Ks | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação |
US10722471B2 (en) | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
CN108601741B (zh) | 2016-02-03 | 2022-05-24 | 诺华股份有限公司 | 有机化合物的盖伦制剂 |
US11096928B2 (en) | 2016-10-08 | 2021-08-24 | Wuhan Ll Science And Technology Development Co., Ltd. | Pharmaceutical composition |
WO2018211479A1 (en) | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
WO2019020706A1 (en) | 2017-07-28 | 2019-01-31 | Synthon B.V. | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
CN110237071B (zh) | 2018-03-09 | 2022-03-22 | 武汉朗来科技发展有限公司 | 药物制剂及其应用 |
JP2021525791A (ja) | 2018-08-23 | 2021-09-27 | ノバルティス アーゲー | 新たな心不全治療用医薬の使用 |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
WO2021158084A1 (ko) * | 2020-02-07 | 2021-08-12 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
KR20200020746A (ko) | 2020-02-07 | 2020-02-26 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
KR20210101164A (ko) | 2020-02-07 | 2021-08-18 | 보령제약 주식회사 | 하이브리드 화합물 및 그 제조방법 |
KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1256692A (en) * | 1991-02-06 | 1992-09-07 | Schering Corporation | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
CA2168066A1 (en) * | 1995-02-08 | 1996-08-09 | James R. Powell | Treatment of hypertension and congestive heart failure |
JP2003533440A (ja) * | 2000-04-03 | 2003-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤 |
CA2411882C (en) * | 2000-06-22 | 2011-09-06 | Novartis Ag | Solid valsartan pharmaceutical compositions |
PE20020613A1 (es) * | 2000-07-19 | 2002-08-07 | Novartis Ag | Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1 |
US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
-
2003
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Application Discontinuation
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/en active Application Filing
- 2003-01-16 EP EP03704413A patent/EP1467728B1/en not_active Expired - Lifetime
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko active IP Right Review Request
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
- 2003-01-16 CA CA2472399A patent/CA2472399C/en not_active Expired - Lifetime
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
-
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
-
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
-
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
-
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
- 2016-05-18 CY CY2016013C patent/CY2016013I1/el unknown
- 2016-05-18 NO NO2016009C patent/NO2016009I2/no unknown
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122018015003B8 (pt) | kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais | |
RU2012144414A (ru) | Комбинация адапалена и пероксида бензоила для лечения поражений акне | |
ES2188214T3 (es) | Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico. | |
BR0009564A (pt) | Utilização de inibidores da cyp2d6 em terapias de combinação | |
BRPI0607569A2 (pt) | composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária | |
ECSP077387A (es) | Composiciones que contienen piperacilina, tazobactam y un ácido aminocarboxílico en un diluyente de lactato de sodio | |
BR9917080A (pt) | Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica | |
BR0008911A (pt) | Bactérias patogênicas da cepa lactobacillus para a prevenção de diarréia | |
CA2258920A1 (en) | Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies | |
BR9906597A (pt) | Produto de prostaglandina | |
MEP33708A (en) | Pharmaceutical compositions comprising a hmg coa reductase inhibitor | |
ECSP045441A (es) | Nueva sal de perindopril y composiciones farmacéuticas que lo contienen | |
UY27639A1 (es) | Composiciones farmacéuticas de inhibidores de la proteína de transferencia de ésteres de colesterilo | |
UY28138A1 (es) | Intermedio de formulación aceptablemente no higroscópico que comprende un fármaco higroscópico | |
MA30966B1 (fr) | Combinaison d'inhibiteurs de iap et d'inhibiteurs de flt3 | |
ATE409485T1 (de) | Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend | |
DOP2002000445A (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
TR199700878T1 (xx) | Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar. | |
BR0015256A (pt) | Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano | |
RU2008108832A (ru) | Композиция и способ применения при заболеваниях, поражающих хрящ | |
NO20016232D0 (no) | Amorfe salpetersyre-estere og farmasöytiske preparater inneholdene disse | |
BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
BR9611642A (pt) | Compostos composição farmacéutica e processo para a preparação de compostos | |
FR2846883B1 (fr) | Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/01/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 16/01/2023 |